RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids

Respiratory Syncytial Virus (RSV) Virology and Bronchiolar Histopathology

Acute bronchiolitis is the single most common lower respiratory tract infection of infancy and the leading cause of pediatric hospital admissions worldwide. It is characterized by acute inflammation, edema, and epithelial necrosis of the smallest conducting airways (bronchioles <1 mm in internal diameter).

Viral Etiology and Epidemiology

• Respiratory Syncytial Virus (RSV): An enveloped, negative-sense, single-stranded RNA virus of the Pneumoviridae family, RSV accounts for 60% to 80% of all clinical bronchiolitis presentations. RSV expresses two major surface glycoproteins: the G glycoprotein (which mediates viral attachment to respiratory ciliated cells) and the F glycoprotein (fusion protein, which mediates viral entry into host cells and syncytia formation by fusing adjacent infected cells).
• Other Viral Pathogens: Human Rhinovirus (HRV, specifically HRV-C, which is strongly associated with recurrent wheezing and later childhood asthma), Human Metapneumovirus (hMPV), Parainfluenza viruses, Bocavirus, Influenza, and Coronaviruses.
• Epidemiology: Exhibits a pronounced seasonal epidemic pattern throughout Europe, typically running from October/November to March/April, with a seasonal peak in December and January. Nearly 100% of children are infected with RSV by 2 years of age, with approximately 2% to 3% of all infants requiring hospital admission during their first winter.
• Peak Age Incidence: Bronchiolitis predominantly affects infants younger than 12 months, with a peak incidence and highest severity occurring between 2 and 6 months of age, coinciding with the physiological nadir of transplacentally acquired maternal neutralizing antibodies.

Histopathology and Pathomechanics

1. Epithelial Inoculation and Cytolysis: Viral replication initiates in the nasopharyngeal mucosa and spreads down the respiratory tree via cell-to-cell transfer. RSV directly infects ciliated bronchiolar epithelial cells, triggering extensive cellular necrosis, apoptosis, and loss of ciliary function.
2. Peribronchial Inflammation: A dense mononuclear cell infiltrate (predominantly CD8+ T lymphocytes, macrophages, and neutrophils) invades the peribronchial and submucosal tissue, causing prominent submucosal edema.
3. Luminal Occlusion: The combination of sloughed necrotic epithelial cells, hypersecreted viscous mucus, fibrin, and cellular debris forms dense intraluminal plugs. Because infant bronchioles lack collateral ventilation (pores of Kohn and canals of Lambert are rudimentary until 6–8 years of age), this debris causes widespread, patchy airway occlusion.
4. Ventilation-Perfusion (V/Q) Mismatch:
   • Partial Occlusion: Creates a ball-valve obstruction, allowing inspiratory gas entry but trapping gas during expiration, producing marked dynamic hyperinflation and alveolar distension.
   • Complete Occlusion: Trapped distal gas is rapidly absorbed into the pulmonary capillary blood, causing subsegmental and patchy resorption atelectasis.
   • Blood perfusing non-ventilated, atelectatic alveoli results in profound intrapulmonary right-to-left shunting, generating significant ventilation-perfusion mismatch and arterial hypoxemia.

---

Clinical Progression, Staging, and High-Risk Cohorts

The Natural History and Clinical Course

The clinical trajectory of acute viral bronchiolitis follows a predictable timeline that is critical for clinical decision-making and parental counseling:

[Day 1 - 3: Upper Respiratory Prodrome]
- Mild coryza, clear rhinorrhea, sneezing, low-grade fever (<38.5°C)
                 |
                 v
[Day 3 - 5: Lower Respiratory Tract Peak Severity]
- Tachypnoea (RR 60-80/min), subcostal/intercostal retractions, nasal flaring
- Auscultation: Fine end-inspiratory crackles + high-pitched expiratory wheeze
- Feeding difficulties (<50% normal volume) due to tachypnoea-swallow mismatch
                 |
                 v
[Day 6 - 10+: Gradual Recovery Phase]
- Work of breathing improves, appetite returns
- Cough frequently persists for 2 to 3 weeks (post-viral airway clearance)

High-Risk Cohorts for Severe Disease and PICU Admission

Certain pediatric populations possess reduced physiological pulmonary reserve and an immature immunological response, placing them at heightened risk for life-threatening respiratory failure, severe apnoea, and intensive care admission:

---

Evidence-Based Supportive Management Protocols

Because no targeted antiviral therapy exists for general clinical use in bronchiolitis, high-quality supportive care directed at fluid balance, nutrition, and oxygenation remains the foundational standard of medical management.

Fluid and Nutrition Management

Infants with bronchiolitis may struggle to coordinate feeding and breathing, particularly when tachypneic or distressed. Assess alertness, work of breathing, swallowing, intake and hydration together; respiratory rate alone does not determine feeding safety.

1. Oral Feeding: Support breastfeeding or smaller, frequent feeds when the infant can feed safely. Reassess if feeding increases distress or causes choking, fatigue or inadequate intake.
2. Enteral Tube Feeding (Nasogastric / Orogastric): Use NG/OG fluids when oral intake is inadequate, often below 50–75% of usual intake with clinical concern. Enteral hydration is generally preferred when tolerated. The major randomized trial found no significant difference in hospital stay between NG and IV hydration; NG insertion was more often successful on the first attempt.
3. Intravenous Hydration: Use isotonic IV fluids when enteral fluids are not tolerated or the infant has impending respiratory failure. Severe distress, recurrent apnoea or exhaustion requires urgent senior assessment of both respiratory support and feeding route.

Oxygen Therapy and Monitoring

Use the locally applicable oxygen protocol. NICE uses the following age- and risk-specific thresholds:

• Supplemental Oxygen Threshold: Give oxygen for persistent SpO2 <90% at age ≥6 weeks, or <92% below 6 weeks or at any age with an underlying health condition. Assess severe distress, apnoea or exhaustion urgently regardless of SpO2; oxygen does not replace ventilatory support.
• Delivery: Delivered via low-flow humidified nasal cannulae (0.5 to 2 L/min) or humidified face mask.
• Discontinuation: Trial withdrawal as the infant improves and maintains the age/risk-appropriate saturation in room air. Before discharge, document over 90%, or over 92% for the higher-risk group, for 4 hours including sleep, alongside clinical stability and adequate intake.
• Continuous vs Spot-Check Oximetry: Continuous pulse oximetry in clinically stable, non-oxygen-dependent infants artificially prolongs hospital length of stay due to normal physiological transient desaturations. Oximetry should transition to intermittent spot checks as the infant stabilizes.

---

Escalating Respiratory Support: High-Flow Nasal Cannula (HFNC)

Heated Humidified High-Flow Nasal Cannula (HFNC) therapy has revolutionized the management of moderate-to-severe bronchiolitis failing conventional low-flow oxygen.

Mechanisms of Action

HFNC delivers blended air and oxygen heated to physiological body temperature (37°C) and 100% relative humidity at high flow rates:

1. Pharyngeal Dead Space Washout: Flushes the anatomical nasopharynx between breaths, washing out expired CO2-rich gas and creating an upper airway reservoir of fresh gas, substantially reducing rebreathing and metabolic ventilatory work.
2. Dynamic Positive Airway Pressure (PEEP): Generates a low-level, flow-dependent positive end-expiratory pressure (approximately 2 to 4 cmH2O at recommended flows when the mouth is closed). This counteracts intrinsic airway collapse, recruits atelectatic alveoli, and increases functional residual capacity (FRC).
3. Overcoming Inspiratory Resistance: Matches or exceeds the infant's peak inspiratory flow demand, dramatically diminishing the muscular work of breathing.
4. Mucociliary Preservation: Physiological heating and complete humidification prevent airway epithelial drying, promote ciliary clearance of viscous secretions, and prevent bronchoconstriction induced by cold, dry gas.

Clinical Implementation Protocol

• Flow Rate: Initiated at 2.0 L/kg/min for the first 10 kg of body weight (typically 1.5 to 2.0 L/kg/min). For children >10 kg, add 0.5 L/kg/min for each additional kilogram.
• FiO2 Titration: Titrate oxygen to the age/risk-appropriate saturation target using the minimum effective FiO2. A rising requirement, particularly >0.50, or persistent distress requires urgent senior/PICU review rather than simply increasing oxygen.
• Prong Sizing: Nasal prongs must occlude no more than 50% of the internal nares diameter to ensure an adequate leak around the prongs, preventing unchecked barotrauma and subcutaneous air leaks.
• Clinical Response: A positive clinical response (defined by a significant reduction in respiratory rate by >15–20% and marked reduction in work of breathing) should be evident within 60 to 90 minutes. Failure to improve mandates urgent escalation to Continuous Positive Airway Pressure (CPAP) or PICU transfer.

---

The "Choosing Wisely" Mandate: Definitive Evidence of Futility

Randomized trials and evidence-based guidelines support supportive care rather than routine drug treatment for uncomplicated bronchiolitis. A recommendation against routine use is not an absolute contraindication when a separate clinical indication exists. The table summarizes routine bronchiolitis care:

---

Discharge Criteria and Parental Safety-Netting

An infant hospitalized with bronchiolitis is clinically ready for discharge when all of the following criteria are fulfilled:

1. Hemodynamic and Respiratory Stability: Clinically stable with a respiratory rate <60 breaths/min and no significant work of breathing (absence of grunting, nasal flaring, or severe intercostal retractions).
2. Adequate Oxygenation: In room air for 4 hours including sleep, maintain SpO2 over 90% at age ≥6 weeks, or over 92% below 6 weeks or with an underlying health condition (NICE).
3. Adequate Enteral Intake: Consuming at least 60% to 75% of normal fluid requirements orally without fatigue, choking, or vomiting.
4. Social and Caregiver Readiness: Caregivers are confident in assessing the infant's work of breathing, understand feeding support, and have access to emergency services.
5. Explicit Red Flag Safety-Netting: Seek immediate medical help for apnoea, cyanosis, worsening work of breathing (grunting, marked chest recession or RR >70/min), exhaustion, intake falling to 50–75% of normal, or no wet nappy for 12 hours.

---

Prevention: Monoclonal Antibody Immunoprophylaxis

Nirsevimab: Universal Infant Protection

• Pharmacology: A recombinant human IgG1κ long-acting monoclonal antibody that binds specifically to the highly conserved antigenic site Ø on the prefusion (pre-F) conformation of the RSV F glycoprotein, neutralizing viral entry.
• Modified Fc Domain: Engineered with a triple amino acid substitution (M252Y/S254T/T256E [YTE]) in the Fc region that dramatically extends its serum elimination half-life to 60 to 80 days.
• Clinical Administration: Administered as a single intramuscular injection that confers sustained protection against lower respiratory tract infection for at least 5 months, covering the entire typical European winter RSV season.
  • Dose: 50 mg IM for infants weighing <5 kg; 100 mg IM for infants weighing ≥5 kg.
• European Indication: Approved and widely adopted across European national immunization programs for all neonates and infants entering or born during their first RSV season, reducing RSV-associated hospitalizations by >80%.

Palivizumab: Targeted High-Risk Protection

• Pharmacology: Humanized murine monoclonal antibody targeting antigenic site II of the RSV F glycoprotein.
• Regimen: Requires monthly intramuscular injections of 15 mg/kg (up to 5 monthly doses throughout the RSV season).
• Contemporary Role: Historically the primary prophylactic agent; largely superseded by nirsevimab because of its single-dose convenience and longer duration of action, but remains an alternative for select infants with chronic lung disease of prematurity (BPD) or hemodynamically significant congenital heart disease where national programs dictate.